2. Academic Validation
  3. Isoprenaline alleviates diabetic kidney disease via multi-target inhibition of the cGAS-STING pathway

Isoprenaline alleviates diabetic kidney disease via multi-target inhibition of the cGAS-STING pathway

  • Biosci Rep. 2026 May 20;46(5):BSR20250174. doi: 10.1042/BSR20250174.
Runtao Ma # 1,  Yue Song # 1,  Lijun Zhang # 1,  Peng Wang 2,  Jiaqi Chen 1,  Tianqi Chen 1,  Guangyao Zhu 2,  Qingrong Pan 1,  Mengyu Ma 2,  Qigui Mo 2,  Surui Lu 1,  Xuanjie Yu 3,  Yi Guo 1
Affiliations

Affiliations

  • 1 School of Basic Medical Sciences, Xianning Medical College, Hubei University of Science and Technology, Xianning 437100, China.
  • 2 School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning 437100, China.
  • 3 Radiology, Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning 437100, China.
  • # Contributed equally.
PMID: 41795784 DOI: 10.1042/BSR20250174
Abstract

Diabetic kidney disease (DKD) is a common microvascular complication of diabetes and is closely linked to chronic inflammation. The present study examined how the β-adrenergic receptor agonist isoprenaline (ISO) protected against DKD by regulating the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling pathway through multiple targets. In a streptozotocin-induced diabetic mouse model, ISO treatment improved glomerulosclerosis, reduced podocyte injury and proteinuria, and suppressed renal inflammation. Network pharmacology and molecular docking suggested that, besides activating ADRB1/2, ISO may interact with Akt1, Src, GSK3β, and EGFR, which are involved in cGAS-STING signaling regulation. These findings indicate that ISO alleviates DKD by inhibiting excessive activation of the cGAS-STING pathway through multi-target coordination, providing a new perspective for therapeutic development.

Keywords

Diabetic kidney disease; Inflammatory response; Isoprenaline; cGAS–STING pathway.

Figures
Products